Synopsis: Shares of Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) witnessed an explosive rally on Thursday, March 12, 2026, surging nearly 12% to hit an intraday high of ₹201.50. The surge followed the board’s official approval of a ₹40 crore buyback proposal at a price of ₹250 per share, representing a substantial premium of over 40% from its previous closing price.

Jagsonpal Pharma Buyback Price Set at ₹250 With ₹40 Crore Approval

The Mumbai-based gynaecology and orthopaedics specialist emerged as a top gainer in the pharma space today.

This marks the Jagsonpal Pharma’s first-ever share buyback, a move aimed at rewarding shareholders and optimizing its capital structure following a stable Q3 FY26 performance.

Investors cheered the aggressive pricing, which signaled management’s strong confidence in the stock’s intrinsic value.

The Buyback Breakdown: Key Details for Investors

The board meeting held today finalized the size and mechanism of the capital return program.

• Buyback Price: ₹250 per equity share, set at a ~42% premium to the March 11 closing price of ₹179.
• Total Size: Up to ₹40 crore (excluding taxes and transaction costs).
• Number of Shares: Jagsonpal Pharma plans to repurchase approximately 16 lakh equity shares, representing roughly 2.39% of the total paid-up equity capital.
• Mechanism: The buyback will be conducted via the “Tender Offer” route, ensuring that existing shareholders (including retail investors) have a reserved category to participate.

Financial Rationale: Why Now?

Jagsonpal’s decision to initiate a buyback comes on the heels of improving financial metrics and a “debt-free” balance sheet.

1. Surplus Cash Utilization: As of December 2025, the company maintained healthy free reserves. By extinguishing these shares, Jagsonpal will improve its Earnings Per Share (EPS) and Return on Equity (ROE).
2. Branded Generics Growth: Management recently highlighted a 6% YoY revenue growth in Q3 FY26. Jagsonpal Pharma is pivoting toward a high-margin “AI-First” sales model to penetrate underserved therapeutic areas in rural India.
3. Mukul Agrawal Portfolio: The stock remains a notable holding in ace investor Mukul Agrawal’s portfolio, adding to the retail interest following this corporate action.

Also read: Bull Market vs Bear Market: Navigating India’s 2026 Stock Market Volatility

Intraday Performance & Key Dates (March 12, 2026)

The stock hit its highest level since January 2025, supported by a 10x surge in trading volume.

Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk.

forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.